Macro
Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.
month values ▾
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0.30 | +0.30 | +0.50 | +0.30 | +0.30 | +0.30 | +0.30 | +0.30 | +0.30 | +0.40 | +0.40 | +0.40 |
The healthcare sector is modestly positive this month, driven primarily by the FDA's approval of the first HIV antibody blood test to enhance blood supply safety—a notable advancement in public health infrastructure. While broader market stability provides context, the sentiment gain is rooted in this regulatory milestone, which signals progress in diagnostic innovation and strengthens confidence in blood screening protocols.
How this mood is scored ▾
The FDA has licensed Abbott Laboratories to market the first HIV antibody test for screening the U.S. blood supply, to be used on 12 million annual donations. The test is expected to prevent 50–150 AIDS cases yearly but may initially reveal high rates of exposure, with a $6 increase per blood unit. False positives and cost concerns have prompted federal funding for accessible testing to prevent misuse of blood donation for screening.